

NEW DOCUMENTS SHOW YEARS OF WARNINGS AND WORKAROUNDS BEFORE NIH SCIENTISTS WERE CHARGED WITH ATTEMPTING TO SMUGGLE MONKEYPOX INTO U.S.

On January 25, 2026, two National Institutes of Health (NIH) Rocky Mountain Laboratories virologists Vincent Munster and Claude Kwe landed at Detroit Metropolitan Airport after a nine-day trip to the Republic of the Congo, where a monkeypox outbreak was underway. They were carrying a large black plastic case that they falsely told Customs officers contained only diagnostics and testing equipment. Inside, investigators found 113 microcentrifuge tubes packed in Styrofoam coolers. Of the 20 the FBI has since tested, 17 contained deactivated monkeypox virus, one contained chickenpox virus, and two contained only human DNA. On June 2, 2026, Munster and Kwe were charged with conspiracy to smuggle monkeypox into the United States and making false statements to federal law enforcement.

Today, Chairman Paul is releasing new documents from the Committee's ongoing investigation showing that this was not an isolated lapse, but part of a broader pattern of treating rules for moving dangerous pathogens as negotiable, stretching back at least a decade.

WHAT THE DOCUMENTS SHOW

- 1 EcoHealth Alliance discussed having Munster hand-carry samples on a commercial flight.**

In a 2011 email about shipping samples from Congo to NIH's Rocky Mountain Laboratories, an EcoHealth Alliance researcher noted that the courier could not transport dry ice and floated an alternative: "take our chances" shipping some samples in lysis buffer and serum on wet ice, while Munster could "hand carry" another set in viral transport media on dry ice during a later trip. "I think you can take up to 2kg with you on commercial flights," the researcher wrote.
- 2 "Just diagnostics" had a history within this research network.**

In 2013, NIH moved to distribute a Jordan strain of MERS coronavirus to a group of investigators that included Munster at Rocky Mountain Laboratories and Ralph Baric at the University of North Carolina. The shipment NIH sent to the Baric Lab was incorrectly labeled as "diagnostic, not infectious," a mistake flagged as "a big problem." The shipment also lacked an itemized list of contents and the dangerous-goods declaration.
- 3 Officials previously warned Munster that improper shipments could become a national scandal.**

In December 2021, Munster told colleagues he would arrange an international shipment of the Omicron variant "without the involvement of NIH shipping." An NIH official warned him, in writing, that doing so risked becoming "a Washington Post moment or congressional inquiry," and noted that his facility, Rocky Mountain Laboratories, had no approved shipping procedures on file.
- 4 Pathogen samples in this network had gone missing in transit before.**

In a 2022 email exchange with the subject line "inactivation diagnostic lysis buffers MPX," a colleague asked Munster whether he had ever recovered his luggage; Munster replied, "[n]o, so no Congo basin clade for now," indicating the lost luggage had carried Congo Basin monkeypox material. In a separate 2022 exchange, a collaborator urged Munster to contact DARPA "asap" about sending coronavirus samples to the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID); Munster replied that he would, adding that "numbnuts lost the first shipment."
- 5 Returning from the Congo with monkeypox samples had happened before.**

In April 2024, Kwe wrote that he and his colleagues had "just returned from the Congo with DNA from MPOX positive samples." A related NIH sequencing request logged 35 monkeypox virus DNA samples derived from human patients and answered "Yes" when asked whether the samples contained or were derived from a regulated "select agent."

From: Jon Epstein <[REDACTED]@ecohealthalliance.org>

To: "Feldmann, Heinrich (NIH/NIAID) [E]" <[REDACTED]@niaid.nih.gov>, "Munster, Vincent (NIH/NIAID) [F]" <[REDACTED]@nih.gov>, 'Patricia Reed' <[REDACTED]@yahoo.com>, Ken Cameron <[REDACTED]@wcs.org>, "William B. Karesh, D.V.M" <[REDACTED]@ecohealthalliance.org>

Subject: RE: Update on World Courier shipping of samples from Congo

Date: Fri, 16 Sep 2011 19:05:37 -0400

Importance: Normal

Inline-Images: image004.jpg; image001.jpg

I'm pretty sure dry ice is available in Kinshasa as well, but the rep said that World Courier actually uses some third party cargo company that won't ship anything with dry ice.

Unfortunately, November is probably too late to begin processing the samples because our grant is due Dec 7th, and we'd want to have the data to include in the preliminary section.

Another option is that we could take our chances shipping the samples in lysis buffer with the serum samples on wet ice, and then when Vincent is over in November perhaps he could hand carry the other set of samples in VTM on dry ice? I think you can take up to 2kg with you on commercial flights.

-Jon

Jonathan H. Epstein DVM, MPH

Associate Vice President



EcoHealth Alliance

| 460 West 34th Street – 17th floor | New York, NY 10001

[REDACTED] (direct) | [REDACTED] (mobile) | [REDACTED] (EHA office)

www.ecohealthalliance.org

EcoHealth Alliance empowers local conservation scientists worldwide to protect nature and safeguard ecosystem and human health.

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:[REDACTED]@niaid.nih.gov]

Sent: Friday, September 16, 2011 6:49 PM

To: Jon Epstein; Munster, Vincent (NIH/NIAID) [F]; 'Patricia Reed'; Ken Cameron; William B. Karesh, D.V.M

Subject: RE: Update on World Courier shipping of samples from Congo

This is strange – all BSL4 shipments that World Courier does for us are on dry ice. The entire IATA transport system is based on dry ice shipment. Could the reason be a lack of access to dry ice? In that case, I think you can get dry ice from Kinshasa.

I am sure that the serum will be fine on wet ice. The other option is that we use the class III cabinets for aliquoting (we could even use the portable ones for those specimens). This way we can keep an aliquot for future analysis. Vincent will be back in Brazzaville in November and could work on that if this is not too late.

Heinz

From: Jon Epstein [mailto:██████████@ecohealthalliance.org]

Sent: Friday, September 16, 2011 3:36 PM

To: Munster, Vincent (NIH/NIAID) [F]; 'Patricia Reed'; Ken Cameron; Feldmann, Heinrich (NIH/NIAID) [E]; William B. Karesh, D.V.M

Subject: Update on World Courier shipping of samples from Congo

Importance: High

Hi guys,

I just spoke with World Courier about transporting the bat samples from Brazzaville to Hamilton Montana. The good news is that they will pick up from Brazzaville. However, we have a challenge with respect to cold chain:

- 1) They cannot provide, nor will they transport dry ice. I asked about whether they would transport a dry shipper, and the representative thought so, but is getting confirmation
- 2) My understanding is that we don't have access to a dry shipper in Brazzaville, and that it could take weeks, if not longer to buy one and get it set up for sample transport (am I correct?)

So, I have two thoughts about this, and I defer to Heinz and Vincent on this... Should we attempt to transport only the sera on wet ice packs? I'm thinking that at least antibodies are fairly stable and though the samples will thaw, we should still be able to detect EBOV antibodies if they're present. Or, do you think we could send the throat, rectal, and urine swabs in Nuclisens lysis buffer as well, with the hope that nucleic acid would survive a thaw process as well? I would have liked to send the set in VTM, but I'm sure we would lose any opportunity to culture virus without proper cold chain.

The samples would go via France (the World Courier office based there is in charge of Congo). I didn't, but will ask if they could add dry ice to the package once it reaches France for the transit between there and the US, for what it's worth.

Is there another way to source a dry shipper rapidly? From Kinshasa? Any other thoughts?

I started a job order for the shipment with our account: Job #9400, if anyone needs to reference it.

Thanks,

Jon

Jonathan H. Epstein DVM, MPH

Associate Vice President



EcoHealth Alliance

| 460 West 34th Street – 17th floor | New York, NY 10001

██████████ (direct) | ██████████ (mobile) | ██████████ (EHA office)

www.ecohealthalliance.org

EcoHealth Alliance empowers local conservation scientists worldwide to protect nature and safeguard ecosystem and human health.

From: [REDACTED] (NIH/NIAID) [E]" <[REDACTED]@niaid.nih.gov>

To: [REDACTED] (NIH/NIAID) [E]" <[REDACTED]@niaid.nih.gov>

Subject: FW: MERS CoV

Date: Thu, 22 Jan 2015 09:47:09 -0500

Importance: Normal

This is the email about the incident we know about.

[REDACTED]

[REDACTED]

Biologist
NIH/NIAID/LID/ERVS

[REDACTED]

fax [REDACTED]

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: <Sims>, Amy Sims <[REDACTED]@email.unc.edu>

Date: Monday, September 23, 2013 2:01 PM

To: "Vogel, Leatrice (NIH/NIAID) [E]" <[REDACTED]@niaid.nih.gov>

Cc: Kanta Subbarao <[REDACTED]@niaid.nih.gov>, [REDACTED] (NIH/NIAID) [E]"

<[REDACTED]@niaid.nih.gov>, "Baric, Ralph" <[REDACTED]@email.unc.edu>

Subject: Re: MERS CoV

Dear Kanta and Lea,

I have been out for the last three weeks on various trips.

I am officially back now and sifting through piles of emails and documents.

As such I have just realized that there was a big problem with the shipment of MERS from you guys. It was shipped as diagnostic, not infectious.

There's nothing that I can do about it now but this might cause us issues with the CDC.

In the paperwork I've been given there was no itemized list of what was included the shipment.

Can you please provide me with a letter stating what was in the shipment that I can include with the documentation I do have? The CDC prefers to see the dangerous goods declaration but obviously one wasn't generated for this shipment.

I appreciate it. Thank you, Amy

On Sep 3, 2013, at 10:58 AM, Vogel, Leatrice (NIH/NIAID) [E] wrote:

Also, please note that as the virus has been amplified in a laboratory setting UNC's Environmental Health and Safety office requires that the virus be shipped as a category A infectious substance.

We can provide shipping materials if need be but the virus must be shipped with this documentation.

I mention this as the shipment to Vanderbilt went category B.

Our Fedex number is [REDACTED] and if the following could be added as the customer number or PO that would be great! [REDACTED]

If you have any questions please let me know.

Thank you so much! Amy

Begin forwarded message:

From: "Sims, Amy C" <[REDACTED]@email.unc.edu<mailto:[REDACTED]@email.unc.edu><mailto:[REDACTED]@email.unc.edu>>>
Date: July 29, 2013 5:51:48 PM EDT
To: "[REDACTED]@niaid.nih.gov<mailto:[REDACTED]@niaid.nih.gov><mailto:[REDACTED]@niaid.nih.gov>"
<[REDACTED]@niaid.nih.gov<mailto:[REDACTED]@niaid.nih.gov><mailto:[REDACTED]@niaid.nih.gov>>, "Vogel, Leatrice
(NIH/NIAID)" <[REDACTED]@niaid.nih.gov<mailto:[REDACTED]@niaid.nih.gov><mailto:[REDACTED]@niaid.nih.gov>>, [REDACTED]
(NIH/NIAID)" <[REDACTED]@mail.nih.gov<mailto:[REDACTED]@mail.nih.gov><mailto:[REDACTED]@mail.nih.gov>>
Cc: "Baric, Ralph S" <[REDACTED]@email.unc.edu<mailto:[REDACTED]@email.unc.edu><mailto:[REDACTED]@email.unc.edu>>>
Subject: Fwd: MERS CoV

Hi,

This is Amy Sims from the Baric lab.

I've attached the CDC import permit form filled out for us to acquire the Jordan strain of MERS-CoV.

Would you please review it and make sure that I haven't made any errors?

Also, UNC's EHS requires that we receive the virus as a category A infectious shipment. Is there anything I can do to help with the shipment?

Do you need anything else from me while we wait for the permit to be approved?

Thank you, Amy

-----Original Message-----

From: Subbarao, Kanta (NIH/NIAID) [E] [mailto:[REDACTED]@niaid.nih.gov]

Sent: Tuesday, June 25, 2013 10:55 AM

To: Baric, Ralph S; Denison, Mark (NIH); Munster, Vincent (NIH/NIAID) [E];

[REDACTED]@gmail.com<mailto:[REDACTED]@gmail.com><mailto:[REDACTED]@gmail.com>

Cc: [REDACTED] CDR USARMY MEDCOM AFHSC (US); [REDACTED] (NIH/NIAID) [E]; Vogel, Leatrice (NIH/NIAID) [E]

Subject: MERS CoV

Dear Ralph, Mark, Vincent and Matt-

I received the MERS CoV isolate from Jordan from [REDACTED] at NAMRU-3 in Egypt through [REDACTED] (cced) in the Armed Forces Health Surveillance Center (AFHSC). I asked [REDACTED] for permission to share the virus with you.

If you read the email chain below, you will see that [REDACTED] has said that 'We have no problem with your sharing aliquots with the colleagues mentioned in your email. All we ask is the opportunity to foster future research between your colleagues and ours and that AFHSC-GEIS and NAMRU-3 (especially [REDACTED]) be acknowledged in published research involving this pathogen.'

I am sure you will not hesitate to agree to this and that you will honor his request.

Please send me a copy of your CDC shipping permit and cc [REDACTED] and Lea. The name of the virus is MERS-CoV Hu/Jordan-N3/2012

We will have to run your paperwork by our Safety office but will work to get you an aliquot as soon as possible.

Best regards,
Kanta

--

Kanta Subbarao, MD, MPH

Chief, Emerging Respiratory Viruses Section Laboratory of Infectious Diseases, NIAID, NIH [REDACTED]

Phone: [REDACTED]

Fax: [REDACTED]

Email: [REDACTED]@niaid.nih.gov<mailto:[REDACTED]@niaid.nih.gov><mailto:[REDACTED]@niaid.nih.gov>

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

On 6/25/13 10:18 AM, [REDACTED] CDR USARMY MEDCOM AFHSC (US)"

<[REDACTED].mil@mail.mil<mailto:[REDACTED].mil@mail.mil>><mailto:[REDACTED].mil@mail.mil>>
wrote:

Classification: UNCLASSIFIED
Caveats: NONE

Kanta,
Glad to hear the work is going well. We have no problem with your sharing aliquots with the colleagues mentioned in your email. All we ask is the opportunity to foster future research between your colleagues and ours and that AFHSC-GEIS and NAMRU-3 (especially [REDACTED]) be acknowledged in published research involving this pathogen.

Also, I'm in the midst of arranging the delivery of another aliquot to the Naval Medical Research Center in Maryland. I've already asked that they supply you with another aliquot once they have grown it sufficiently and they have agreed. I assume you are still interested in acquiring and additional sample? Let me know.

[REDACTED]

[REDACTED] PhD
CDR, PHS
Leader, Respiratory Pillar Activities
Division of GEIS
Armed Forces Health Surveillance Center (AFHSC)
[REDACTED]
Phone: [REDACTED]
Mobile: [REDACTED]
E-mail: [REDACTED].mil@mail.mil<mailto:[REDACTED].mil@mail.mil>
<mailto:[REDACTED].mil@mail.mil>

-----Original Message-----

From: Subbarao, Kanta (NIH/NIAID) [E] [mailto:[REDACTED]@niaid.nih.gov]
Sent: Tuesday, June 25, 2013 9:41 AM
To: [REDACTED] J CDR USARMY MEDCOM AFHSC (US)
Cc: [REDACTED] COL USARMY MEDCOM AFHSC (US); [REDACTED] (NIH/NIAID) [E]
Subject: MERS CoV

Dear [REDACTED] -

The Jordan isolate that we received from N3 grew well in cell culture, so we are preparing to begin some experiments. Thank you for your help in getting this virus.

From the email correspondence with Dr. Lisa Hensley at the NIAID IRF in Frederick, I understood that we had your permission to share the virus with her.

Several other people have been asking whether they can get an aliquot. I am including their names and affiliations below:

Ralph Baric, Univ of North Carolina
Mark Denison, Vanderbilt Univ
Matthew Frieman, Univ of Maryland
Vincent Munster, NIAID Rocky Mountain Lab

All of these investigators have BSL3 (or BSL4 in the case of RML) labs and are experienced virologists. Please let me know if I can direct them to you for permission. I would be happy to ship the virus to them if you cc me.

Thank you again. Please let me know if there are projects that we could work on together. Is there an effort to do some serosurveys in members of the military who have been stationed in the region?

Best wishes,

Kanta

--

Kanta Subbarao, MD, MPH
Chief, Emerging Respiratory Viruses Section Laboratory of Infectious

[Redacted]

Phone: [Redacted]

Fax: [Redacted]

Email: [Redacted] [@niaid.nih.gov](mailto:[Redacted]@niaid.nih.gov) <[mailto:\[Redacted\]@niaid.nih.gov](mailto:[Redacted]@niaid.nih.gov)> <[mailto:\[Redacted\]@niaid.nih.gov](mailto:[Redacted]@niaid.nih.gov)>

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Classification: UNCLASSIFIED
Caveats: NONE

Amy C. Sims, Ph.D.

[REDACTED]

Office:

[REDACTED]

[REDACTED] [@ad.unc.edu](mailto:[REDACTED]@ad.unc.edu) <[mailto:\[REDACTED\]@ad.unc.edu](mailto:[REDACTED]@ad.unc.edu)> <[mailto:\[REDACTED\]@ad.unc.edu](mailto:[REDACTED]@ad.unc.edu)>

Amy C. Sims, Ph.D.

[REDACTED]

Office:

[REDACTED]

[REDACTED] [@ad.unc.edu](mailto:[REDACTED]@ad.unc.edu) <[mailto:\[REDACTED\]@ad.unc.edu](mailto:[REDACTED]@ad.unc.edu)> <[mailto:\[REDACTED\]@ad.unc.edu](mailto:[REDACTED]@ad.unc.edu)>

Amy C. Sims, Ph.D.

[REDACTED]

Office:

[REDACTED]

[REDACTED] [@ad.unc.edu](mailto:[REDACTED]@ad.unc.edu) <[mailto:\[REDACTED\]@ad.unc.edu](mailto:[REDACTED]@ad.unc.edu)>

Amy C. Sims, Ph.D.

[REDACTED]

Office:

[REDACTED]

[REDACTED] [@ad.unc.edu](mailto:[REDACTED]@ad.unc.edu)

From: "Knox, Shamay (NIH/NIAID) [E]" <[REDACTED]@niaid.nih.gov>
To: "Holland, Steven (NIH/NIAID) [E]" <[REDACTED]@niaid.nih.gov>, "Munster, Vincent (NIH/NIAID) [E]" <[REDACTED]@nih.gov>, "Embry, Alan (NIH/NIAID) [E]" <[REDACTED]@niaid.nih.gov>, "Degrace, Marciela (NIH/NIAID) [E]" <[REDACTED]@nih.gov>, "Post, Diane (NIH/NIAID) [E]" <[REDACTED]@niaid.nih.gov>, "Handley, Gray (NIH/NIAID) [E]" <[REDACTED]@niaid.nih.gov>, "Grewe, Charles (NIH/NIAID) [E]" <[REDACTED]@niaid.nih.gov>, "Kennedy, George (NIH/NIAID) [E]" <[REDACTED]@mail.nih.gov>
Cc: "Menk, Kay (NIH/NIAID) [E]" <[REDACTED]@niaid.nih.gov>
Subject: RE: omicron update
Date: Thu, 02 Dec 2021 17:34:25 -0500
Importance: Normal

Hi everyone,

I'm adding Chuck Grewe (NIAID's Chief CO and OA Director) and George Kennedy (NIAID OA Policy Branch Chief).

George's branch is going to look into this issue for us. This is a tricky situation because if we ship materials ourselves without the authority to do so, and outside of the federal policy, it only takes one shipment to go wrong for it to end up as a Washington Post moment or congressional inquiry, like so many other acquisition/grant issues lately. This is a minor acquisition but given the nature of what we ship it could be high risk to NIAID, particularly in this climate.

The Authority for international shipments is similar to the authority for leasing space in that it rests with GSA, and can be delegated under certain conditions. GSA controls Technical Service Orders (TSO) Shipping. When the NIH OD DLS office receives a request for shipping, they provide a Government Bill of Lading to the GSA administration. Then GSA procures the shipping on our behalf.

The exception that is referenced in the policy (that Kay noted) states that, the IC's are able to use other appropriate mechanisms to purchase, but only after a policy is written and approved they the Director of DLS, see below:

*Appendix A: Supplement to Manual Chapter 26101-42-F; Section E.1.c.
Delegated Authority to Procure Shipping Services*

The NIH Institutes/Centers (IC) activities below are delegated specific authority to procure shipping services and issue Government Bills of Lading (GBL), or to use other appropriate mechanisms to pay delivery charges. These IC locations/activities must produce written procedures to assure compliance with this policy and will forward those procedures to the Director, DLS for approval. Report of shipping activities will be provided as required by the Director, DLS.

Although RML is listed as a site that could receive an exception, it does not currently have an approved SOP and process on file with DLS (we checked to confirm). That's probably where the previous confusion occurred... that the location is listed and perhaps it was assumed an SOP was in place. In order for us to procure these services, RML should produce one and gain approval. We don't have experience with this, or know what the SOP should contain, or the proper procedures to ensure we stay on the legal side of it.

We are awaiting more information from the DLS office, but will engage OA's policy branch in taking this effort on from here.

Vincent, I'm unclear on your note below (I highlighted it in red). How do you plan to procure it?

Shamay

From: "Munster, Vincent (NIH/NIAID) [E]" <[REDACTED]@nih.gov>
Date: Thursday, December 2, 2021 at 9:48 AM
To: Steven Holland <[REDACTED]@niaid.nih.gov>, "Embry, Alan (NIH/NIAID) [E]" <[REDACTED]@niaid.nih.gov>, "Degrace, Marciela (NIH/NIAID) [E]" <[REDACTED]@nih.gov>, "Post, Diane (NIH/NIAID) [E]" <[REDACTED]@niaid.nih.gov>, "Handley, Gray (NIH/NIAID) [E]" <[REDACTED]@niaid.nih.gov>, Shamay Knox <[REDACTED]@niaid.nih.gov>
Cc: "Menk, Kay (NIH/NIAID) [E]" <[REDACTED]@niaid.nih.gov>
Subject: omicron update

Hi guys,

Just heard back from Hong Kong, we will have a shipment hopefully coming in soon (early next week), we will directly distribute to [REDACTED] (Emory) for distribution throughout the SAVE network

Shamay: just to give you a heads-up we will arrange shipment from our end without the involvement of NIH shipping. It is absolutely critical that NIH and US researchers get access to the omicron variant ASAP

Let me know if there are any further questions,

Cheers,

Vincent Munster, PhD
Chief Virus Ecology Section
Rocky Mountain Laboratories
NIAID/NIH

From: "Munster, Vincent (NIH/NIAID) [E]" <[REDACTED]@nih.gov>

To: "Fischer, Robert (NIH/NIAID) [F]" <[REDACTED]@niaid.nih.gov>

Subject: RE: inactivation diagnostic lysis buffers MPX

Date: Mon, 18 Jul 2022 10:41:23 -0400

Importance: Normal

Nope, so no Congo basin clade for now

Vincent Munster, PhD
Chief Virus Ecology Section
Rocky Mountain Laboratories
NIAID/NIH

From: Fischer, Robert (NIH/NIAID) [F] <[REDACTED]@niaid.nih.gov>

Sent: Friday, July 15, 2022 9:52 AM

To: Munster, Vincent (NIH/NIAID) [E] <[REDACTED]@nih.gov>

Subject: RE: inactivation diagnostic lysis buffers MPX

Vincent,
Did you ever get your luggage?
Bob

From: Munster, Vincent (NIH/NIAID) [E] <[REDACTED]@nih.gov>

Sent: Friday, July 15, 2022 9:04 AM

To: Relich, Ryan Ford <[REDACTED]@iupui.edu>; Fischer, Robert (NIH/NIAID) [F] <[REDACTED]@niaid.nih.gov>; [REDACTED] (NIH/NIAID) [E] <[REDACTED]@nih.gov>; [REDACTED] (NIH/NIAID) [C] <[REDACTED]@nih.gov>

Subject: inactivation diagnostic lysis buffers MPX

Hi Bob,

Ryan will be sending us some additional diagnostic lyses buffer to test for MPX inactivation. I would suggest you use both [REDACTED] and [REDACTED] to push forward this part. Given the current circumstances getting this data out asap to diagnostic labs will be critical.

[REDACTED] / [REDACTED]: discuss with bob the best possible way to support him

Bob: can you send primer/probes and positive controls to Ryan?

Cheers,

Vincent Munster, PhD
Chief Virus Ecology Section
Rocky Mountain Laboratories
NIAID/NIH

From: "Munster, Vincent (NIH/NIAID) [E]" <[REDACTED]@nih.gov>

To: "Sara LaTrielle" <[REDACTED]@cornell.edu>

Cc: "Raina K. Plowright" <[REDACTED]@cornell.edu>

Subject: RE: Contact DARPA asap, re: CoV samples to USAMRIID

Date: Tue, 09 Aug 2022 16:36:08 -0400

Importance: Normal

Will do, numbnuts lost the first shipment

Vincent Munster, PhD
Chief Virus Ecology Section
Rocky Mountain Laboratories
NIAID/NIH

From: Sara LaTrielle <[REDACTED]@cornell.edu>

Sent: Tuesday, August 9, 2022 2:28 PM

To: Munster, Vincent (NIH/NIAID) [E] <[REDACTED]@nih.gov>

Cc: Raina K. Plowright <[REDACTED]@cornell.edu>

Subject: [EXTERNAL] Contact DARPA asap, re: CoV samples to USAMRIID

Vincent,

DARPA reached out to us, requesting that you please get in touch with Nathalie asap, and respond to her email on the topic of sending CoV samples to USAMRIID. If they don't hear back from you soon, they may need to 'escalate'.

I'll keep it short, as I know you are busy!

Best,
Sara

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and are confident the content is safe.

From: "Kwe Claude, Yinda (NIH/NIAID) [E]" <[REDACTED]@nih.gov>

To: [REDACTED] (NIH/NIAID) [E]" <[REDACTED]@niaid.nih.gov>

Cc: "Munster, Vincent (NIH/NIAID) [E]" <[REDACTED]@nih.gov>

Subject: Re: ROC Mpox sequencing

Date: Thu, 25 Apr 2024 13:27:24 -0400

Importance: Normal

Attachments: GRS.24-04-25.0135-_Your_Request_has_been_Submitted.eml

Hi [REDACTED],

I didn't hear from you concerning this.

Cheers,
Kwe

From: Kwe Claude, Yinda (NIH/NIAID) [E] <[REDACTED]@nih.gov>

Date: Monday, April 22, 2024 at 11:49 AM

To: [REDACTED] (NIH/NIAID) [E] <[REDACTED]@niaid.nih.gov>

Cc: Munster, Vincent (NIH/NIAID) [E] <[REDACTED]@nih.gov>

Subject: ROC Mpox sequencing

Hi [REDACTED],

I hope this email finds you well. We just returned from the Congo with DNA from MPOX positive samples, and we're eager to perform full genome sequencing on these samples. Our aim is to address critical epidemiological questions surrounding the ongoing MPOX outbreak in Africa.

We have a total of 35 samples with ct values ranging from 15 to 36. Given the direct impact this sequencing will have on the ongoing outbreak response, we would greatly appreciate it if you could prioritize this.

Please let us know your thoughts.

Best regards,
Kwe

From: NIAID RTB TAS Team <[REDACTED]@mail.nih.gov>

To: [REDACTED]@nih.gov

Subject: GRS.24-04-25.0135: Your Request has been Submitted

Date: Thu, 25 Apr 2024 13:25:45 -0400

 NIAID RTB Header

[GRS.24-04-25.0135](#)

Your Request has been Submitted

Genomics Research

Dear Claude Yinda,

Thank you for submitting your request on 04/25/2024 at 1:25 PM EDT via the RTB Technology Accessioning System.

Below are details of the request:

Request ID: [GRS.24-04-25.0135](#)

Status: Pending

Requested By: Claude Yinda Kwe ([REDACTED]@nih.gov | +1 [REDACTED])

Institute: National Institute of Allergy and Infectious Diseases

Section: [Genomics Research](#)

Description: N/A

Files Uploaded:

- [ROC-Mpox_GRS Sample Manifest Template.xlsx](#)

Project Name: Republic of the Congo (ROC) Mpox sequencing

Project Summary: We want to obtain the full genome sequences of mpox DNA from ROC patients following an unprecedented outbreak in the neighboring Democratic Republic of the Congo (DRC) which seems to spillover into ROC.

Data Analysis: - Consensus sequences

- Sequencing depth maps

-

Organism: Other

Other Organism: mpox virus

Experiment Type: Viral Genome

If experiment includes Feature Barcodes or Hash Tags, send sequences to

[REDACTED]@niaid.nih.gov: No

Number Of Samples: 35

Sample Type: DNA

Delivery ETA: 4/24/2024

Would you like the original samples or any derivatives returned to you? If not, all material will be disposed of after 6 months: Yes

Do these samples contain or were derived from a select agent?: Yes

Are these samples derived from human patients and do you have IRB approval for sequencing?: Yes

Would you like RTB (IDSS) to perform data analysis: Yes

CAN: 8010044

To view the status of this request at any time, please visit:

[REDACTED]

Section Contact

[REDACTED], Ph.D.

[REDACTED]@nih.gov

[REDACTED]

RTB Contact

[REDACTED] Ph.D.

[REDACTED]@nih.gov

[REDACTED]

Technical Support Contact

[REDACTED]@mail.nih.gov



[Sign up](#) for govDELIVERY messages.

© 2023 NIH RTB. All Rights Reserved.